International Stem Cell Corporation (ISCO) Teaming with Leading Brain Research Center to Advance Development of Powerful Stem Cell Technology
International Stem Cell Corporation (OTCQB: ISCO) is the company behind a powerful new stem cell technology called parthenogenesis, which promises to significantly advance the field of regenerative medicine by addressing the problem of immune-rejection. Derived from unfertilized eggs, the company’s human parthenogenetic stem cells (hPSCs) are pluripotent, meaning that they have the potential to become virtually any cell in the human body. The first pluripotent stem cells to be studied for the purposes of regenerative medicine were embryonic stem cells (ESCs), which were taken from donated human embryos. While these cells could offer considerable healing potential, they also present a…